4//SEC Filing
DeSchuytner Brian 4
Accession 0001104659-25-004592
CIK 0001442836other
Filed
Jan 16, 7:00 PM ET
Accepted
Jan 17, 7:20 PM ET
Size
18.3 KB
Accession
0001104659-25-004592
Insider Transaction Report
Form 4
DeSchuytner Brian
SVP, COO & CFO
Transactions
- Award
Stock Option (Right to Buy)
2025-01-15+281,250→ 281,250 totalExercise: $0.64Exp: 2035-01-14→ Common Stock (281,250 underlying) - Exercise/Conversion
Common Stock
2025-01-15+6,250→ 115,280 total - Exercise/Conversion
Common Stock
2025-01-15+14,583→ 129,863 total - Exercise/Conversion
Restricted Stock Unit
2025-01-15−6,250→ 0 total→ Common Stock (6,250 underlying) - Exercise/Conversion
Restricted Stock Unit
2025-01-15−14,583→ 43,750 total→ Common Stock (14,583 underlying) - Sale
Common Stock
2025-01-16$0.58/sh−8,470$4,913→ 121,393 total - Award
Restricted Stock Unit
2025-01-15+62,500→ 62,500 total→ Common Stock (62,500 underlying)
Footnotes (9)
- [F1]Represents shares of common stock received upon vesting of a portion of the restricted stock units ("RSUs") awarded to the Reporting Person on January 15, 2021.
- [F2]Represents shares of common stock received upon vesting of a portion of the RSUs awarded to the Reporting Person on January 15, 2024.
- [F3]Represents the sale of shares of common stock to satisfy the Reporting Person's tax withholding obligations in connection with the service-based vesting and settlement of the RSUs pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 10, 2023. The sale was effected through an automatic "sell to cover" transaction that did not represent a discretionary trade by the Reporting Person.
- [F4]The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $0.56 to $0.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]Each RSU represents the contingent right to receive one share of common stock of the Issuer.
- [F6]Fully vested as of January 15, 2025.
- [F7]25% of the total number of RSUs granted vested on January 15, 2025, and the remainder shall vest thereafter in equal annual installments over the next three years.
- [F8]The option shall vest in equal quarterly installments over four years from the date of grant.
- [F9]The RSUs shall vest in equal annual installments over four years from the date of grant.
Documents
Issuer
Mersana Therapeutics, Inc.
CIK 0001442836
Entity typeother
Related Parties
1- filerCIK 0001782163
Filing Metadata
- Form type
- 4
- Filed
- Jan 16, 7:00 PM ET
- Accepted
- Jan 17, 7:20 PM ET
- Size
- 18.3 KB